Innate Immunity and SARS-CoV-2 Vaccine Response in Hemodialysis Patients

Kidney360. 2022 Aug 9;3(10):1763-1768. doi: 10.34067/KID.0002542022. eCollection 2022 Oct 27.

Abstract

Patients receiving hemodialysis (HD) have more inflammatory monocytes and less plasmacytoid dendritic cells (DCs) compared with healthy controls.Patients on HD who have a poor antibody response to the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine had fewer monocyte-derived DCs and conventional DCs compared with good responders.The defects in antigen presentation might be possible therapeutic targets to increase vaccine efficacy in HD patients.

Keywords: COVID-19; SARS-CoV-2; basic science; chronic kidney disease; dendritic cell; immune response; innate immunity; mRNA vaccine; monocyte.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • COVID-19 Vaccines*
  • COVID-19* / prevention & control
  • Humans
  • Immunity, Innate
  • Renal Dialysis / adverse effects
  • SARS-CoV-2

Substances

  • COVID-19 Vaccines